Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2006

View Archived Issues

Shire recaps year's successes

Incyte makes considerable progress in fourth quarter

Enrollment completed in first of two phase III studies of AI-700

Digna Biotech and Biotherapix to develop treatment for pulmonary fibrosis

Novo Nordisk reinitiates phase III program for AERx iDMS

Enrollment completed in phase I study of AdPEDF gene therapy

Enrollment open in phase I study of BSI-201 for advanced malignancies

Phase II study of DP-b99 in acute stroke cleared to continue

Baxter opens phase II adult stem cell therapy trial for chronic myocardial ischemia

Juvaris awarded SBIR grant for HIV vaccine development

Quigley files IND for clinical trials of QR-333 in diabetic peripheral neuropathy

Positive results for Zegerid in nocturnal acid breakthrough

Nonapprovable letter for Vadova

Reveromycin A shows potential for osteoporosis

Kyorin's antidiabetic agent KRP-104 begins phase I

Shionogi and Galderma reach initial sales agreement for adapalene gel

N-Acetylcysteine: an antioxidant and MMP inhibitor for oral cancer

European approval for Remicade for ulcerative colitis

EM-011: Potential oral treatment of drug-resistant lymphomas

Novel agents imparted for the treatment of inflammatory disorders

Recent patents impart novel agents for obesity and lipoprotein disorders

Novel analgesic agents disclosed in recent patent literature

Promising results from phase I and II studies in prostate cancer

Preliminary clinical data on efalizumab for the treatment of oral lichen planus reported

Kaken reports preclinical data on its novel leukotriene/thromboxane dual inhibitor KP-496

New preclinical data on Chinese herbal medicine formula presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...